<p>The roll-out of Russian Covid-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again, officials said on Sunday.</p>.<p>"We do not have a clarity on the dates of the vaccine roll-out," a spokesman of Apollo Hospitals said.</p>.<p>Indraprastha Apollo here had earlier said that it would tentatively start administering the two-dose vaccine by June 25.</p>.<p>An official of Madhukar Rainbow Children's Hospital said the facility has also not received Sputnik V doses so far from Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country. </p>.<p>"There is a delay on the part of the suppliers. They have not shared any specific reason for it. I think it could be related to the supply of both the doses together," he said.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/science-and-environment/sputnik-v-to-offer-booster-shot-against-delta-variant-998522.html" target="_blank">Sputnik V to offer booster shot against Delta variant</a></strong></p>.<p>Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. The two doses, given 21 days apart, are different and not interchangeable.</p>.<p>Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.</p>.<p>The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private Covid-19 Vaccination Centres (CVCs) has been fixed at RS 780 per dose, while that of Covaxin at Rs 1,410 per dose.</p>.<p>Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed the vaccine and the Russian Direct Investment Fund (RDIF) is marketing it globally.</p>.<p>Dr Reddy's Laboratories has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India. </p>.<p>According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.</p>
<p>The roll-out of Russian Covid-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again, officials said on Sunday.</p>.<p>"We do not have a clarity on the dates of the vaccine roll-out," a spokesman of Apollo Hospitals said.</p>.<p>Indraprastha Apollo here had earlier said that it would tentatively start administering the two-dose vaccine by June 25.</p>.<p>An official of Madhukar Rainbow Children's Hospital said the facility has also not received Sputnik V doses so far from Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country. </p>.<p>"There is a delay on the part of the suppliers. They have not shared any specific reason for it. I think it could be related to the supply of both the doses together," he said.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/science-and-environment/sputnik-v-to-offer-booster-shot-against-delta-variant-998522.html" target="_blank">Sputnik V to offer booster shot against Delta variant</a></strong></p>.<p>Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. The two doses, given 21 days apart, are different and not interchangeable.</p>.<p>Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.</p>.<p>The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private Covid-19 Vaccination Centres (CVCs) has been fixed at RS 780 per dose, while that of Covaxin at Rs 1,410 per dose.</p>.<p>Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed the vaccine and the Russian Direct Investment Fund (RDIF) is marketing it globally.</p>.<p>Dr Reddy's Laboratories has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India. </p>.<p>According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.</p>